Q3679101 (Q3679101): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: importing one item from France) |
(Created claim: summary (P836): Neurodegenerative diseases (NDDs such as Alzheimer’s disease) are an important medical, scientific, societal and economic issue. The diagnosis of these diseases has improved considerably through the use of clinical-biological biomarkers. The BioManed project is part of this framework and aims, on the one hand, to validate the interest of these biomarkers as predictive markers of the disease and, on the other hand, to discover and confirm new ea...) |
||||||||||||||
| Property / summary | |||||||||||||||
Neurodegenerative diseases (NDDs such as Alzheimer’s disease) are an important medical, scientific, societal and economic issue. The diagnosis of these diseases has improved considerably through the use of clinical-biological biomarkers. The BioManed project is part of this framework and aims, on the one hand, to validate the interest of these biomarkers as predictive markers of the disease and, on the other hand, to discover and confirm new early Alzheimer’s markers using proteomic techniques (protein in biological fluids). (English) | |||||||||||||||
| Property / summary: Neurodegenerative diseases (NDDs such as Alzheimer’s disease) are an important medical, scientific, societal and economic issue. The diagnosis of these diseases has improved considerably through the use of clinical-biological biomarkers. The BioManed project is part of this framework and aims, on the one hand, to validate the interest of these biomarkers as predictive markers of the disease and, on the other hand, to discover and confirm new early Alzheimer’s markers using proteomic techniques (protein in biological fluids). (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Neurodegenerative diseases (NDDs such as Alzheimer’s disease) are an important medical, scientific, societal and economic issue. The diagnosis of these diseases has improved considerably through the use of clinical-biological biomarkers. The BioManed project is part of this framework and aims, on the one hand, to validate the interest of these biomarkers as predictive markers of the disease and, on the other hand, to discover and confirm new early Alzheimer’s markers using proteomic techniques (protein in biological fluids). (English) / qualifier | |||||||||||||||
point in time: 18 November 2021
| |||||||||||||||
Revision as of 16:41, 18 November 2021
Project Q3679101 in France
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3679101 in France |
Statements
60,199.0 Euro
0 references
85,999.0 Euro
0 references
70.0 percent
0 references
20 November 2015
0 references
31 December 2020
0 references
CHU DE MONTPELLIER
0 references
Les maladies neurodégénératives (MND telles que la maladie d'Alzheimer) sont un enjeu médical, scientifique, sociétal et économique important. Le diagnostic de ces maladies s'est considérablement amélioré grâce à l'usage de biomarqueurs clinico-biologiques. Le projet BioManed s'inscrit dans ce cadre et a pour objectif d'une part de valider l'intérêt de ces biomarqueurs comme marqueurs prédictifs de la maladie et d'autre part de découvrir et de confirmer de nouveaux marqueurs d’Alzheimer au stade précoce par des techniques de protéomique (protéine dans les fluides biologiques). (French)
0 references
Neurodegenerative diseases (NDDs such as Alzheimer’s disease) are an important medical, scientific, societal and economic issue. The diagnosis of these diseases has improved considerably through the use of clinical-biological biomarkers. The BioManed project is part of this framework and aims, on the one hand, to validate the interest of these biomarkers as predictive markers of the disease and, on the other hand, to discover and confirm new early Alzheimer’s markers using proteomic techniques (protein in biological fluids). (English)
18 November 2021
0 references
Identifiers
LR0001105
0 references